WASHINGTON, April 13 (UPI) — The U.S. Food and Drug Administration says some inhalers used by asthma and chronic obstructive pulmonary disease patients are being phased out.

The FDA said seven metered-dose inhalers that contain ozone-depleting chlorofluorocarbons will be gradually removed from the U.S. marketplace. Alternative medications that do not contain the ozone-destroying chemicals are available, the federal agency said.

The affected products and their phase out schedule are:

– Tilade Inhaler (nedocromil), made by King Pharmaceuticals. Last date for sale: June 14.

– Alupent Inhalation Aerosol (metaproterenol), made by Boehringer Ingelheim Pharmaceuticals. Last date for sale: June 14.